Business Context and Reporting Period
Allogene Therapeutics, Inc. filed this Form 8-K on October 7, 2021, reporting a clinical development and regulatory event involving its investigational ALLO-501A allogeneic CAR T-cell therapy. The filing is not a quarterly or annual financial report and does not provide financial statements or operating-period results.
Key Financial and Operating Metrics
The filing does not provide revenue, net income, cash flow, margins, debt, liquidity, or other financial metrics.
- ALLO-501A was being evaluated in the ALPHA2 clinical study in a patient with Stage IV transformed follicular lymphoma.
- The patient developed progressive pancytopenia; a bone marrow biopsy identified aplastic anemia and ALLO-501A CAR T cells with a chromosomal abnormality.
- The patient experienced Grade 1 cytokine release syndrome and Grade 2 immune effector cell-associated neurotoxicity syndrome, treated with high-dose steroids.
- The patient had a partial response and subsequently underwent allogeneic stem cell transplantation.
Material Changes Versus the Prior Comparable Period
The filing does not present comparative financial information. The material development reported is that the FDA placed the Company’s clinical trials on hold after Allogene notified the FDA of the chromosomal abnormality observed in the ALPHA2 patient.
Guidance, Outlook, Risks, and Unusual Items
- The Company is investigating the abnormality, including its clinical relevance, possible clonal expansion, and potential relationship to gene editing.
- The Company expects to provide additional updates in the following weeks after consultation with the FDA.
- The FDA continued to review end-of-Phase 1 materials submitted in anticipation of a pivotal Phase 2 ALLO-501A trial.
- The clinical hold may delay ongoing clinical trials, regulatory review, and development of ALLO-501A. The filing does not quantify the potential financial impact or duration of the hold.
- The filing states that prolonged cytopenia requiring rescue stem cell transplantation has been reported in autologous CAR T therapies; however, the clinical significance and cause of this patient’s chromosomal abnormality remained under investigation.
Important Facts for Investors to Verify
- FDA communications regarding the scope, conditions, and duration of the clinical hold.
- Results of the Company’s investigation into the chromosomal abnormality, including any evidence of clonal expansion or connection to gene editing.
- Whether the event affects the planned ALLO-501A pivotal Phase 2 trial or other Allogene clinical programs.
- Subsequent disclosures regarding patient safety, treatment outcomes, and the Company’s financial runway or expected development costs.